GH Secretagogues

GHRP-6

Molecular Identifiers

Molecular Formula

C46H56N12O6

PubChem CID

4345065

Overview

First-generation GH-releasing peptide with strong ghrelin activity. Causes significant appetite increase. Potent GH release.

Extended notation: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

Contains D-amino acids (D-Trp, D-Phe)

Half-life

~15-20 minutes

Administration Route

Subcutaneous

Category

GH Secretagogues

Mechanism of Action

  • High-affinity GHS-R1a receptor agonist
  • Strong ghrelinergic activity (significant appetite increase)
  • Potent GH release
  • May elevate cortisol and prolactin at high doses

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 100-300 mcg per injection
Frequency 2-3 times per day
Timing Morning, post-workout and before bedtime
Duration 8-12 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Intense appetite increase
  • Water retention
  • Elevated cortisol
  • Lethargy

Presentations & Preparation

Vials of GHRP-6 found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per 5 mg vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Room temperature or refrigerated
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on GHRP-6.

1995 · Eur J Endocrinol

Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature

Bellone J, Ghizzoni L, Aimaretti G, Volta C, Boghen MF, Bernasconi S, Ghigo E
1999 · J Neuroendocrinol

Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration

Frieboes RM, Murck H, Antonijevic IA, Steiger A
2006 · Clin Sci (Lond)

Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure

Berlanga J, Cibrian D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Guillen G

Related Peptides

CJC-1295 with DAC

1-2 mg per week · Once per week

CJC-1295 sem DAC

100-200 mcg per injection · 2-3 times daily

GHRP-2

100-300 mcg per injection · 2-3 times per day

Hexarelin

200-300 mcg per injection · 2-3 times per day

Ipamorelin

200-300 mcg per injection · 2-3 times daily

MK-677

10-25 mg per dose · Once daily